Landmarks in hormonal therapy for prostate cancer

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x.


• It is >70 years since the responsiveness of symptomatic metastatic prostate cancer to androgen deprivation was first demonstrated. • Since those pivotal studies, progress in hormonal therapy of prostate cancer has been marked by several important developments and the availability of various androgen-suppressing agents. • Treatment guidelines have continued to evolve with clinical and therapeutic progress, but androgen-deprivation therapy (ADT) remains the standard of care for non-localised prostate cancer. • Because of the long-term experience (>20 years) and wealth of evidence from the large number of clinical trials, the luteinizing hormone-releasing hormone (LHRH) agonists are currently the main forms of ADT. • Treatment strategies should be adapted to the individual patient in terms of timing, duration and choice of agent. • Prostate cancer remains the most common type of cancer in men and the development of castration-resistant disease seems inevitable, which together drive the clear and continuing need for new, effective agents for ADT to be used alongside the LHRH agonists.

Publication types

  • Review

MeSH terms

  • Abiraterone Acetate
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / therapeutic use*
  • Androstadienes / therapeutic use
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Combined Modality Therapy / methods
  • Humans
  • Imidazoles / therapeutic use
  • Male
  • Naphthalenes / therapeutic use
  • Phenylthiohydantoin / analogs & derivatives
  • Phenylthiohydantoin / therapeutic use
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / radiotherapy
  • Treatment Outcome


  • Androgen Antagonists
  • Androstadienes
  • Antineoplastic Agents, Hormonal
  • Imidazoles
  • Naphthalenes
  • Phenylthiohydantoin
  • enzalutamide
  • Abiraterone Acetate
  • orteronel